Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 4/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699525 | 0.86 | GSK3B (0.50) | EP300GSK3BMAPTTBK1WNT1 | |
| SCHEMBL19699553 | 0.80 | DYRK1A (0.57) | EP300GSK3BBRD4CREBBPWNT1 | |
| SCHEMBL23570700 | 0.75 | HIF1A (0.53) | MAPTKDRIDO1 | |
| SCHEMBL19706511 | 0.73 | PIK3C3 (0.53) | GSK3BWNT1DYRK1A | |
| SCHEMBL19699579 | 0.72 | MAPK14 (0.49) | GSK3BMAPTSCN9ANR3C2 | |
| SCHEMBL24932350 | 0.72 | EGFR (0.61) | GSK3BMAPT | |
| SCHEMBL19699548 | 0.70 | PIK3C3 (0.51) | GSK3BMAPTBRD4CREBBP | |
| SCHEMBL19699511 | 0.69 | WNT3A (0.47) | GSK3BMAPTWNT1DYRK1A | |
| SCHEMBL19699527 | 0.69 | GSK3B (0.47) | GSK3BMAPTWNT1DYRK1A | |
| SCHEMBL19962827 | 0.69 | MAPT (0.53) | GSK3BMAPTKDRSCN9ANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | EP300 247/4885GSK3B 2322/4885MAPT 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.